Masataka Tsuge

Hiroshima, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 229 publications

A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment.

A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment.

Journal: Internal medicine (Tokyo, Japan)

Published: August 19, 2026

Utility of intracellular enhancement for improving hepatic lesion visibility at gadoxetic acid-enhanced hepatobiliary-phase MRI.

Utility of intracellular enhancement for improving hepatic lesion visibility at gadoxetic acid-enhanced hepatobiliary-phase MRI.

Journal: European journal of radiology open

Published: May 26, 2026

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

Journal: Microorganisms

Published: March 08, 2026

Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".

Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".

Journal: Journal of gastroenterology

Published: February 26, 2026

Clinical Characteristics and Predictive Factors of Immune-Mediated Cholangitis: A Large Single-Center Retrospective Observational Study.

Clinical Characteristics and Predictive Factors of Immune-Mediated Cholangitis: A Large Single-Center Retrospective Observational Study.

Journal: Cancers

Published: December 30, 2025

Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.

Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.

Journal: Clinical journal of gastroenterology

Published: December 08, 2025

Spatial profiling of chronic liver disease: a pilot spatial case series.

Spatial profiling of chronic liver disease: a pilot spatial case series.

Journal: Scientific reports

Published: December 03, 2025

Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 18, 2025

Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma.

Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma.

Journal: Journal of gastrointestinal oncology

Published: October 11, 2025

Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients.

Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients.

Journal: International journal of molecular sciences

Published: September 21, 2025

Multidisciplinary Treatment With Hepatic Arterial Infusion Chemotherapy, Radiotherapy, and Immunotherapy for Advanced Hepatocellular Carcinoma With Major Vascular Invasion: Prospective Registry Protocol.

Multidisciplinary Treatment With Hepatic Arterial Infusion Chemotherapy, Radiotherapy, and Immunotherapy for Advanced Hepatocellular Carcinoma With Major Vascular Invasion: Prospective Registry Protocol.

Journal: JMIR research protocols

Published: September 06, 2025

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

Journal: Internal medicine (Tokyo, Japan)

Published: September 03, 2025

Showing 1-12 of 229

Last Updated: 09/26/2026